PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1927684
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1927684
The Normothermic Machine Perfusion Market size was valued at US$ 1,590.36 Million in 2024, expanding at a CAGR of 17.95% from 2025 to 2032.
The Normothermic Machine Perfusion (NMP) Market includes technologies and services that keep donor organs at near-physiological body temperature outside the human body, allowing for continuous oxygenation, nutrient delivery, and real-time functional evaluation before transplantation. This strategy is revolutionizing organ preservation by increasing viability and improving post-transplant outcomes. A key driver is the global shortage of transplantable organs, which forces transplant centers to make better use of marginal or extended-criteria organs. A major trend is the use of advanced sensors, biomarkers, and AI-powered analytics to track organ metabolism and predict graft performance. However, high system costs and the need for specialized clinical expertise serve as a barrier to adoption in resource-constrained settings. Despite this, there is a significant opportunity to expand NMP applications beyond liver and kidney transplants to include heart and lung preservation, which is supported by rising transplant volumes, favorable clinical evidence, and increased investment in next-generation organ preservation technologies.
Normothermic Machine Perfusion Market- Market Dynamics
Growing Demand for Organ Transplants Driving Market Expansion
The growing demand for organ transplantation is expected to drive the normothermic machine perfusion market. Organ transplantation is the replacement of a malfunctioning or diseased organ with a healthy one from a donor. The rising prevalence of end-stage organ failure, which is frequently caused by chronic diseases, as well as advances in surgical techniques and immunosuppressive therapies, are driving up the demand for transplants. Normothermic machine perfusion is critical for preserving and reviving donor organs by keeping them at body temperature with oxygenated blood or a perfusate until transplantation. For example, in January 2024, the United States Department of Health and Human Services reported that 46,632 organ transplants were performed in 2023, representing an 8.7% increase over 2022. The growing demand for organ transplants is driving the market for normothermic machine perfusion.
The worldwide market is segmented on the basis of Application, Technology, Category, Offering, End User, and Region.
The product segment is expected to account for a sizable portion of the global normothermic machine perfusion market during the forecast period. The growing use of normothermic machine perfusion products such as systems, reagents, and consumables in organ preservation, viability assessment, and organ reconditioning, is expected to drive up demand for normothermic machine perfusion products. As a result, several major market players are involved in the research and development of new products. This will lead to the introduction of advanced products, thereby increasing their availability and accessibility to healthcare facilities. This is expected to drive segment growth during the forecast period. For example, as of April 2024, Lung Bioengineering is conducting clinical trials on a centralized ex vivo lung perfusion (EVLP) service model in order to increase the pool of usable donor lungs. The successful completion of this clinical study will increase its use and demand in liver organ preservation and transplantation. Thus, R&D activities for novel products are expected to drive segment growth.
Based on Application. the liver segment represented the most normothermic machine perfusion market share. Organ transplants are increasing due to the rising prevalence of chronic diseases that cause liver failure, such as fatty liver disease and hepatitis C. Liver allografts maintain viability after transplantation thanks to NMP technology, which reduces harmful tissue damage and improves liver performance detection for optimal organ management. This technology remains popular in transplant centers around the world because it improves liver quality during preservation before transplantation.
In April 2024, Lung Bioengineering developed a centralized ex vivo lung perfusion (EVLP) service model that will increase the number of usable donor lungs. The useful clinical outcomes of these studies will encourage the use of this preservation method in liver organ transplantation procedures.
Normothermic Machine Perfusion Market- Geographical Insights
North America is expected to account for a significant portion of the normothermic machine perfusion market during the forecast period. The increasing geriatric population is responsible for regional growth, as older people are more likely to experience organ failure than younger people. As a result, the increasing elderly population has a significant impact on the supply and demand for organ transplantation. This is expected to drive regional market growth. For example, the Population Reference Bureau estimates that the number of people aged 65 and older in the United States will increase from 58.0 million in 2022 to 82.0 million by 2050.
United States Normothermic Machine Perfusion Market- Country Insights
The United States is the region's largest contributor, leveraging significant investments in organ transplantation research as well as government policies that encourage the use of transplantation programs and innovative perfusion techniques. The comprehensive reimbursement framework for organ preservation devices also rewards healthcare providers who use normothermic machine perfusion technology. Furthermore, the strong presence of industry leaders such as OrganOx, TransMedics, and Medtronic encourages the ongoing development and marketing of cutting-edge perfusion devices.
In August 2025, a groundbreaking comparative study presented at the World Transplant Congress in California, USA, revealed that Hypothermic Oxygenated Machine Perfusion (HOPE) with the VitaSmart Machine Perfusion System provides better outcomes in liver transplantation than Normothermic Machine Perfusion (NMP). The study found that organ and recipient survival improved with fewer post-transplant complications, such as reduced non-anastomotic strictures (NAS) and NAS-associated graft loss.
The Normothermic Machine Perfusion (NMP) Market is characterized by competitive dynamics between innovative device manufacturers and specialized perfusion technology developers working to improve organ preservation and transplant outcomes. Companies compete based on clinical validation, system versatility, real-time monitoring capabilities, and collaboration with transplant centers and research institutions. Cutting-edge development efforts focus on increasing organ applicability, improving ease of use, and incorporating advanced analytics. Key players in the market include TransMedics, known for its Organ Care System (OCS(TM)) platforms; XVIVO Perfusion, which offers advanced lung perfusion solutions; Vascular Insights, leveraging artificial intelligence for surgical decision support; and LifePort, recognized for its organ transport and perfusion technologies. Other notable participants, such as Vescurta, Fluent Medical, SurgiCor, InnovaHealth, and Prescient Surgical, are increasing competition by developing niche perfusion applications, software integration, and improved organ viability support.
In October 2024, OrganOx Ltd, a world-leading organ medical technology company, received Health Canada approval for the OrganOx Metra System for use in liver transplantation. The United States, the United Kingdom, and the European Union operate a commercially accessible liver transplantation system.
In December 2023, XVIVO has announced the launch of the pilot project in NRP. The company began this project after assessing the attractive business opportunities for NRP, which drew significant interest from U.S. experts in organ recovery methods.